{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:05:12Z","timestamp":1791525912203,"version":"4.3.4"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In 2018, the Cancer Therapy Evaluation Program (CTEP) at the US National Cancer Institute published new protocol template language that focused on organ function and prior and concurrent cancers in an effort to modernize eligibility criteria for cancer treatment trials. We conducted an analysis of CTEP-supported trials to evaluate the uptake and incorporation of the new language. The analysis included evaluation of 122 protocols approved in the years 2018-2020 for inclusion of the modernized eligibility criteria and consistency with new protocol template language related to 7 major eligibility criteria. These were cardiac function, liver function, kidney function, HIV status, prior and\/or concurrent malignancies, treated and\/or stable brain metastasis, and new and\/or progressive brain metastases. Overall, CTEP trials evaluated in this period demonstrated that eligibility criteria were implemented to a relatively high degree ranging from a low of 54.1% for prior and\/or concurrent malignancies to a high of 93.4% for eligibility criteria related to HIV infection. The findings demonstrate that modernized eligibility criteria can be successfully implemented but that consistent implementation requires sustained focused effort. As a result of these findings, CTEP began a new initiative in January 2022 that incorporates a specific review of eligibility criteria for new protocols to promote and improve consistency with the modernization effort.<\/jats:p>","DOI":"10.1093\/jnci\/djac152","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T14:49:43Z","timestamp":1662043783000},"page":"1437-1440","source":"Crossref","is-referenced-by-count":25,"title":["Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials"],"prefix":"10.1093","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-8694","authenticated-orcid":false,"given":"Andrea M","family":"Denicoff","sequence":"first","affiliation":[{"name":"Division of Cancer Treatment & Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute , Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-072X","authenticated-orcid":false,"given":"S Percy","family":"Ivy","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment & Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute , Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami T","family":"Tamashiro","sequence":"additional","affiliation":[{"name":"Emmes , Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxiu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Emmes , Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine H","family":"Worthington","sequence":"additional","affiliation":[{"name":"Emmes , Rockville, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-8331","authenticated-orcid":false,"given":"Margaret M","family":"Mooney","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment & Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute , Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4091-1699","authenticated-orcid":false,"given":"Richard F","family":"Little","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment & Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute , Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"issue":"33","key":"2022111508113083300_djac152-B1","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2022111508113083300_djac152-B2","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-20-3852","article-title":"Continuing to broaden eligibility criteria to make clinical trials more representative and inclusive: ASCO-Friends of Cancer Research joint research statement","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2022111508113083300_djac152-B3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger","year":"2019","journal-title":"JAMA Oncol"},{"issue":"33","key":"2022111508113083300_djac152-B4","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"2022111508113083300_djac152-B5","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1056\/NEJMp1615879","article-title":"Reevaluating eligibility criteria\u2013balancing patient protection and participation in oncology trials","volume":"376","author":"Beaver","year":"2017","journal-title":"N Engl J Med"},{"key":"2022111508113083300_djac152-B6","first-page":"71654","article-title":"Enhancing the diversity of clinical trial populations\u2014eligibility criteria, enrollment practices, and trial designs guidance for industry","volume":"85","author":"U.S. Department of Health and Human Services Food and Drug Administration","year":"2020","journal-title":"Federal Register"},{"issue":"5","key":"2022111508113083300_djac152-B7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1001\/jama.2018.18938","article-title":"Modernizing clinical trials for patients with cancer","volume":"321","author":"Sharpless","year":"2019","journal-title":"JAMA"},{"issue":"suppl 15","key":"2022111508113083300_djac152-B8","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1200\/JCO.2021.39.15_suppl.6518","article-title":"National Cancer Institute (NCI) implementation of the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) broadening clinical trials eligibility criteria","volume":"39","author":"Denicoff","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"2022111508113083300_djac152-B9","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2015-08-664706","article-title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the (BMT CTN) 0803\/(AMC) 071 trial","volume":"128","author":"Alvarnas","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2022111508113083300_djac152-B10","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.bbmt.2019.06.033","article-title":"Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903\/AMC-080 trial","volume":"25","author":"Ambinder","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2022111508113083300_djac152-B11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/jamaoncol.2018.6437","article-title":"Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices","volume":"5","author":"Ramsey","year":"2019","journal-title":"JAMA Oncol"},{"issue":"suppl 15","key":"2022111508113083300_djac152-B12","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1200\/jco.2009.27.15_suppl.6538","article-title":"Randomized clinical trial eligibility rates for chemotherapy (CT) and antiangiogenic therapy (AAT) in a population-based cohort of newly diagnosed non-small cell lung cancer (NSCLC) patients","volume":"27","author":"Fehrenbacher","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"2022111508113083300_djac152-B13","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1158\/1078-0432.CCR-16-0338","article-title":"Challenges facing early phase trials sponsored by the National Cancer Institute: an analysis of corrective action plans to improve accrual","volume":"22","author":"Massett","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2022111508113083300_djac152-B14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1634\/theoncologist.2017-0687","article-title":"Characterization of comorbidities limiting the recruitment of patients in early phase clinical trials","volume":"24","author":"Duma","year":"2019","journal-title":"Oncologist"},{"issue":"25","key":"2022111508113083300_djac152-B15","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2014.60.4165","article-title":"Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials","volume":"33","author":"Meric-Bernstam","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"2022111508113083300_djac152-B16","first-page":"e999","article-title":"Accessing targeted therapies: a potential roadblock to implementing precision oncology?","volume":"17","author":"von Itzstein","year":"2021","journal-title":"J Clin Oncol Pract"},{"key":"2022111508113083300_djac152-B17","author":"National Cancer Institute Clinical Trials and Translational Research Advisory Committee (CTAC) Strategic Planning Working Group","year":"2020"},{"issue":"12","key":"2022111508113083300_djac152-B18","doi-asserted-by":"crossref","first-page":"e2027110","DOI":"10.1001\/jamanetworkopen.2020.27110","article-title":"Assessment of cancer therapy evaluation program advocacy and inclusion rates of people living with HIV in anti-PD1\/PDL1 clinical trials","volume":"3","author":"Reuss","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djac152\/45955143\/djac152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/114\/11\/1437\/47018362\/djac152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/114\/11\/1437\/47018362\/djac152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T08:11:48Z","timestamp":1668499908000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/114\/11\/1437\/6680187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,9,1]]},"published-print":{"date-parts":[[2022,11,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djac152","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,9,1]]}}}